Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04077021 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Calibr, a division of Scripps Research.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04077021 is a Phase 1 study that was terminated before completion, run by Calibr, a division of Scripps Research. The registered enrollment target is 22 participants.
The verdict
NCT04077021, a Phase 1 study, was terminated before completion, sponsored by Calibr, a division of Scripps Research.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. Part I is divided in to two subparts, in both subparts patients will receive ascending dosages of CCW702 with the goal to determine the maximum tolerated dose (MTD) of CCW702 and efficacious regimen. Part Ia will explore every other other day dosing (QOD); Part Ib will explore weekly dosing (Q7D). In part II of the study, patients will be given the recommended part/phase 2 dose (RP2D) Q7D. The study will also assess the pharmacokinetics and pharmacodynamics of CCW702.
Interventions
- DRUG CCW702
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-07-17 |
| Est. Completion | 2022-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04077021
The ClinicalTrials.gov registry entry for NCT04077021 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calibr, a division of Scripps Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CCW702 is the first listed.
NCT04077021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04077021 about?
NCT04077021 is a clinical study titled "First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer". CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. Part I is divided in to two subparts, in both subpar...
What is the current status of trial NCT04077021?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-07-17. Estimated completion is 2022-10-21.
What interventions are being tested in trial NCT04077021?
The interventions under investigation include: CCW702 (DRUG).
Who is sponsoring clinical trial NCT04077021?
This trial is sponsored by Calibr, a division of Scripps Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.